Le traitement du cancer du testicule

Jean Pierre Droz, Helen Boyle, Stéphane Culine, Karim Fizazi, Aude Fléchon, Christophe Massard

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    2 Citations (Scopus)

    Résumé

    Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose chemotherapy). Clinical stage I testicular cancer is the most common presentation and different strategies are proposed: Adjuvant therapies, surgery or surveillance. During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs.

    Titre traduit de la contributionTreatment of testicular cancer
    langue originaleFrançais
    Pages (de - à)1319-1332
    Nombre de pages14
    journalBulletin du Cancer
    Volume100
    Numéro de publication12
    Les DOIs
    étatPublié - 1 janv. 2013

    mots-clés

    • Cisplatin
    • Germ-cell tumor
    • Residual masses
    • Testicular cancer

    Contient cette citation